{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:12:06Z","timestamp":1753877526199,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11-12","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AG036778","R21AG058348","R01HL139671"],"award-info":[{"award-number":["K24AG036778","R21AG058348","R01HL139671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer, Prothena, Eidos and Alnylam"},{"name":"Vertex, Grifols International SA, CSL Behring and Arrowhead Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Wild-type ATTR cardiac amyloidosis (ATTRwt-CA) is not as rare as previously thought to be. Patients with infiltrative cardiac amyloidosis often present with right-sided heart failure (HF) symptomatology. Clinically significant liver disease and cirrhosis has not been reported in ATTRwt-CA. We present two cases of ATTRwt-CA with right-sided HF and abnormal liver function tests initially thought to be secondary to congestive hepatopathy but found to have rare and unrelated liver disease. These cases highlight the importance of developing a broad differential diagnosis and leveraging a multidisciplinary team approach in evaluating patients for unusual causes of cirrhosis\/other chronic liver diseases when ATTR cardiac amyloidosis patients present with congestive hepatopathy.<\/jats:p>","DOI":"10.1093\/omcr\/omab113","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T10:43:07Z","timestamp":1638355387000},"source":"Crossref","is-referenced-by-count":1,"title":["Can lightning strike twice? Wild-type transthyretin cardiac amyloidosis associated with rare liver disease"],"prefix":"10.1093","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6922-7084","authenticated-orcid":false,"given":"Priyanka T","family":"Bhattacharya","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson N","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C","family":"Marboe","sequence":"additional","affiliation":[{"name":"Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M","family":"Lagana","sequence":"additional","affiliation":[{"name":"Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen E","family":"Remotti","sequence":"additional","affiliation":[{"name":"Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanine M","family":"D\u2019Armiento","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica P","family":"Goldklang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew B","family":"Eisenberger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M","family":"Griffin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew S","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"2021122815195872700_ref1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2021122815195872700_ref2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2021122815195872700_ref3","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2021122815195872700_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-020-02275-1","article-title":"Wild-type transthyretin cardiac amyloidosis: when is a rare disease no longer a rare disease?","author":"Wechalekar","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2021122815195872700_ref5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122815195872700_ref6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249420","article-title":"Congestive Hepatopathy","volume":"21","author":"Fortea","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2021122815195872700_ref7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha1-antitrypsin deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N Engl J Med"},{"key":"2021122815195872700_ref8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0068-2017","article-title":"COPD in individuals with the PiMZ alpha-1 antitrypsin genotype","volume":"26","author":"Al Ashry","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2021122815195872700_ref9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.14309\/ajg.0000000000000315","article-title":"ACG clinical guideline: hereditary hemochromatosis","volume":"114","author":"Kowdley","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2021122815195872700_ref10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179369","article-title":"ERAD defects and the HFE-H63D variant are associated with increased risk of liver damages in alpha 1-antitrypsin deficiency","volume":"12","author":"Joly","year":"2017","journal-title":"PLoS One"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/11-12\/omab113\/41940609\/omab113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/11-12\/omab113\/41940609\/omab113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T15:53:24Z","timestamp":1640706804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omab113\/6439724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":10,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omab113","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,11,1]]},"article-number":"omab113"}}